{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T23:12:14Z","timestamp":1781133134302,"version":"3.54.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.exphem.2026.105386","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:29:19Z","timestamp":1770222559000},"page":"105386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Taking the direct route: menin inhibitors go straight to the frontline in KMT2A-rearranged acute leukemia"],"prefix":"10.1016","volume":"156","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6432-6999","authenticated-orcid":false,"given":"Anjum B.","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.P.","family":"Huntly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2026.105386_bib0001","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41408-021-00557-6","article-title":"Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements","volume":"11","author":"Issa","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2026.105386_bib0002","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis","volume":"123","author":"Yokoyama","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2026.105386_bib0003","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/17501911.2025.2485019","article-title":"Menin: from molecular insights to clinical impact","volume":"17","author":"Brown","year":"2025","journal-title":"Epigenomics"},{"key":"10.1016\/j.exphem.2026.105386_bib0004","article-title":"Upfront menin-inhibitor resistance in multiply pretreated leukemias","volume":"153","author":"Mahdavi","year":"2025","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2026.105386_bib0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2026.105386_bib0006","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2026.105386_bib0007","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2026.105386_bib0008","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ccr.2014.03.016","article-title":"MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia","volume":"25","author":"Chen","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2026.105386_bib0009","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2159-8290.CD-22-0416","article-title":"A molecular switch between mammalian MLL complexes dictates response to menin-MLL inhibition","volume":"13","author":"Soto-Feliciano","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.exphem.2026.105386_bib0010","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s41375-022-01741-8","article-title":"UTX loss alters therapeutic responses in KMT2A-rearranged acute myeloid leukemia","volume":"37","author":"Zhou","year":"2023","journal-title":"Leukemia"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X26000196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X26000196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T12:31:50Z","timestamp":1773750710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X26000196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":10,"alternative-id":["S0301472X26000196"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2026.105386","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Taking the direct route: menin inhibitors go straight to the frontline in KMT2A-rearranged acute leukemia","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2026.105386","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Experimental Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105386"}}